Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Bone Marrow Transplantation

Volumn 39, Issue 9, 2007, Pages 523-527

  Kamezaki, K ^a   Kikushige, Y ^a   Numata, A ^b   Miyamoto, T ^a   Takase, K ^b   Henzan, H ^b   Aoki, K ^c   Kato, K ^b   Nonami, A ^a   Kamimura, T ^d   Arima, F ^b   Takenaka, K ^a   Harada, N ^a   Fukuda, T ^a,e   Hayashi, S ^d   Ohno, Y ^c   Eto, T ^b   Harada, M ^a   Nagafuji, K ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b HAMANOMACHI HOSPITAL   (Japan)

^c KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^d HARASANSHIN HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RANIMUSTINE; RITUXIMAB; STEM CELL FACTOR; VERY LATE ACTIVATION ANTIGEN 4; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG MEGADOSE; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN CELL; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 34247394534     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705649     Document Type: Article

References (26)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
2. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586-592.
3. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
4. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol 2004; 15: 283-290.
5. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
6. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
8. Flinn IW, Lazarus HM. Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2001; 27 565-569.
9. Nademanee A, Forman SJ. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Semin Hematol 2006; 43: 240-250.
10. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S et al. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 115-122.
11. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864-869.
12. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139-143.
13. Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4561-4566.
14. Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/ progenitor cell mobilization. Blood 2004; 103: 1580-1585.
15. Imamura R, Miyamoto T, Yoshimoto G, Kamezaki K, Ishikawa F, Henzan H et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol 2005; 175 2647-2654.
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
17. Teshima T, Harada M, Takamatsu Y, Makino K, Inaba S, Akashi K et al. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol 1993; 84: 570-573.
18. Makino S, Harada M, Akashi K, Taniguchi S, Shibuya T, Inaba S et al. A simplified method for cryopreservation of peripheral blood stem cells at -80 degrees C without rate-controlled freezing. Bone Marrow Transplant 1991; 8: 239-244.
19. Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S et al. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemo-sensitivity and gene expression profiling. Pharmacol Res 2006; 53: 49-61.
20. van Heeckeren WJ, Vollweiler J, Fu P, Cooper BW, Meyerson H, Lazarus HM et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006; 132: 42-55.
21. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
22. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691-2694.
23. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913-918.
24. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106: 795-802.
25. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 921-923.
26. Cairoli R, Grillo G, Tedeschi A, D'Avanzo G, Marenco P, Morra E.. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89 361-363.